Lin Fang
Impact in
- Cancer Research top 0.5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 2%
- Circular RNAs in diseases
- RNA modifications and cancer
- RNA Research and Splicing
- RNA Interference and Gene Delivery
Papers in
-
- MicroRNA in disease regulation 57
- Cancer-related molecular mechanisms research 50
-
- Circular RNAs in diseases 50
- RNA Research and Splicing 25
- RNA modifications and cancer 22
- RNA Interference and Gene Delivery 18
Lin Fang
211 papers receiving 5.8k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Cancer Research 2.3k
- Molecular Biology 3.5k
- Oncology 1.0k
- Immunology 744
- Pathology and Forensic Medicine 350
Countries citing papers authored by Lin Fang
This map shows the geographic impact of Lin Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Fang more than expected).
Fields of papers citing papers by Lin Fang
This network shows the impact of papers produced by Lin Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Fang. The network helps show where Lin Fang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lin Fang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 2 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 1 | |
| 6 | 2024 | 4 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 4 | |
| 9 | 2024 | 4 | |
| 10 | 2024 | 8 | |
| 11 | 2024 | 1 | |
| 12 | 2024 | 8 | |
| 13 | 2022 | 30 | |
| 14 | Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer Hit paper breakdown → | 2021 | 170 |
| 15 | Hydrogen Sulfide Protects Against High Glucose-Induced Human Umbilical Vein Endothelial Cell Injury Through Activating PI3K/Akt/eNOS Pathway | 2020 | 4 |
| 16 | 2016 | 136 | |
| 17 | Analysis of Echinococcosis Infection among Teenagers in Xiji County | 2012 | 1 |
| 18 | 2012 | 43 | |
| 19 | An indirect ELISA using a soluble protein E2 as antigen for detection of antibodies to classical swine fever virus. | 2009 | 1 |
| 20 | The experimental studies of a novel hENDO-VEGI_ (151) fusion gene therapy on gastric carcinoma in nude mice mediated by adenovirus vector | 2005 | 1 |
About Lin Fang
Lin Fang is a scholar working on Cancer Research, Molecular Biology, Oncology, Polymers and Plastics and Pathology and Forensic Medicine, having authored 226 papers that have together received 5.9k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (57 papers), Cancer-related molecular mechanisms research (50 papers), Circular RNAs in diseases (50 papers), RNA Research and Splicing (25 papers), RNA modifications and cancer (22 papers), RNA Interference and Gene Delivery (18 papers), Virus-based gene therapy research (10 papers) and Hippo pathway signaling and YAP/TAZ (10 papers). The work is most often cited by research in Cancer Research (2.3k citations), Molecular Biology (3.5k citations), Oncology (1.0k citations), Immunology (744 citations) and Pathology and Forensic Medicine (350 citations). Lin Fang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Huizhong Zhang, Xuehui Wang, Ke Dong, Hongming Song, Qifeng Luo, Xi Wang, Kaiyao Hua, Xiaoyu Li, Junyong Zhao and Xiangjie Kong. Their work appears in journals such as Oncology Reports, Cellular Signalling, Cancer Biology & Therapy, International Journal of Oncology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.